Needham & Company on Hi Tech Pharmacal (HITK): Four Reason to Buy the Stock Here
Tweet Send to a FriendGet Alerts HITK Hot Sheet
Price: $33.81 +0.21%
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 14
Rating Summary:
3 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 14
Trade HITK Now!
Needham & Company maintains a 'Buy' on Hi Tech Pharmacal (NASDAQ: HITK) price target of $45.00.
Analyst, Randall Stanicky, said, "As anticipated, EPS missed consensus but largely on transitory issues. With a widely anticipated tough fiscal Q4 now past, we see four reasons to buy the stock here: (1) we leave fiscal Q4 with greater comfort in outer year numbers which move higher; (2) balance sheet is cash rich at > $6 per share on a stock at < $30; (3) asset base is high barrier with strategic value and progressing pipeline; and (4) valuation is compelling at ~ 4.1x EV/EBITDA on F2014E (April). While we recognize a lack of obvious near-term catalysts as push-back, we also recognize a sizable cash balance that is likely to draw attention."
For an analyst ratings summary and ratings history on Hi Tech Pharmacal click here. For more ratings news on Hi Tech Pharmacal click here.
Shares of Hi Tech Pharmacal closed at $29.97 yesterday, with a 52 week range of $23.72-$44.58.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Randall Stanicky, said, "As anticipated, EPS missed consensus but largely on transitory issues. With a widely anticipated tough fiscal Q4 now past, we see four reasons to buy the stock here: (1) we leave fiscal Q4 with greater comfort in outer year numbers which move higher; (2) balance sheet is cash rich at > $6 per share on a stock at < $30; (3) asset base is high barrier with strategic value and progressing pipeline; and (4) valuation is compelling at ~ 4.1x EV/EBITDA on F2014E (April). While we recognize a lack of obvious near-term catalysts as push-back, we also recognize a sizable cash balance that is likely to draw attention."
For an analyst ratings summary and ratings history on Hi Tech Pharmacal click here. For more ratings news on Hi Tech Pharmacal click here.
Shares of Hi Tech Pharmacal closed at $29.97 yesterday, with a 52 week range of $23.72-$44.58.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
- UPDATE: Exane BNP Paribas Downgrades BlackBerry (BBRY) to Underperform; Analyst Says Profit 'Drying Up'
- Jefferies Bumps PT on Home Depot (HD) to $91
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Needham & Company
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
